Dennis Aeling’s practice focuses on large-scale patent litigation matters with an emphasis in pharmaceuticals and chemistry. Prior to practicing law, Dennis worked for a contract research organization in the analytical chemistry group, identifying and characterizing small molecules. Dennis’s technical experience includes work on such diverse technologies as antibacterial agents, antihistamines, immunosuppressants, muscarinic agonists for the treament of Sjögrens Syndrome, ophthalmic formulations and prostate cancer treatments.
Dennis helped secure a complete victory in a Hatch-Waxman litigation for clients, Pfizer, Inc., Merck & Co., and InSite Vision against generic drug manufacturer Sandoz, Inc. After a seven day bench trial the district court found that Sandoz’s generic eye drops infringed every asserted claim of four patents held by our clients, and that those claims were not invalid for obviousness. This decision was unanimously affirmed by the Court of Appeals for the Federal Circuit.